Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 1/2 2

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid 1Leukemia 1Bronchiolitis Obliterans Syndrome 1

Interventions

Specimen Handling 123Magnetic Resonance Spectroscopy 99Biopsy 72pembrolizumab 58Carboplatin 55Nivolumab 54Cisplatin 53Cyclophosphamide 51Paclitaxel 41Bevacizumab 36Radiotherapy 33Gemcitabine 33Dexamethasone 30Doxorubicin 25atezolizumab 24Fluorouracil 24olaparib 23Rituximab 23Pemetrexed 23fludarabine 22durvalumab 21Radiation 21Cytarabine 21venetoclax 20Vincristine 20Prednisone 20Oxaliplatin 20Ipilimumab 20Injections 20Lenalidomide 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × asciminib × 30 days × Clear all
NCT05143840 2026-06-02

ALERTCML

University of Alabama at Birmingham

Phase 2 Recruiting
100 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT07354074 2026-05-26

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Novartis

Phase 2 Recruiting
50 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡